Api Details

Vildagliptin is a vital pharmaceutical API used in the management of type 2 diabetes mellitus. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing insulin secretion and reducing glucagon production in response to elevated blood sugar levels. This helps to lower blood sugar levels and improve glycemic control in diabetic patients. Administered orally, typically in tablet form, dosages vary based on individual patient needs and response. While generally well-tolerated, potential side effects may include headache, nausea, and hypoglycemia. Regulatory adherence ensures stringent quality and safety standards during manufacturing, ensuring reliability in Vildagliptin-containing pharmaceutical products.